Vor Biopharma (VOR)
14.19
+1.19 (9.15%)
Upcoming Events
Latest Headlines
Form 8-K Vor Biopharma Inc. For: Jun 08
June 8, 2026 4:02 PM - SEC Filing
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
June 8, 2026 8:31 AM - Globe NewsWire
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
June 8, 2026 8:30 AM - Globe NewsWire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026 5:00 PM - Globe NewsWire
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.
May 15, 2026 4:38 PM - SEC Filing
Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Verve Capital Ltd
May 15, 2026 4:34 PM - SEC Filing
Vor Bio reports positive telitacicept trial results in kidney disease
May 14, 2026 8:30 AM - StreetInsider
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
May 14, 2026 8:30 AM - Globe NewsWire
Form 10-Q Vor Biopharma Inc. For: Mar 31
May 13, 2026 8:32 AM - SEC Filing
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026 8:30 AM - Globe NewsWire
Form EFFECT Vor Biopharma Inc.
May 7, 2026 6:08 AM - SEC Filing
Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: Qiming Venture Partners VIII-HC, L.P.
May 6, 2026 4:17 PM - SEC Filing
Form SCHEDULE 13G/A Vor Biopharma Inc. Filed by: FMR LLC
May 6, 2026 11:41 AM - SEC Filing
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026 4:30 PM - Globe NewsWire
Vor Biopharma (VOR) files for 5.34M share offering by selling stockholders
April 27, 2026 4:14 PM - StreetInsider
Form S-3 Vor Biopharma Inc.
April 27, 2026 4:12 PM - SEC Filing
Form ARS Vor Biopharma Inc. For: Dec 31
April 27, 2026 4:02 PM - SEC Filing
Form DEFA14A Vor Biopharma Inc.
April 27, 2026 4:02 PM - SEC Filing
Form DEF 14A Vor Biopharma Inc. For: Apr 23
April 27, 2026 4:01 PM - SEC Filing
Form 4 Vor Biopharma Inc. For: Apr 22 Filed by: Kolchinsky Peter
April 24, 2026 6:13 PM - SEC Filing
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
April 21, 2026 7:06 PM - SEC Filing
Form 4 Vor Biopharma Inc. For: Apr 17 Filed by: Kolchinsky Peter
April 21, 2026 7:04 PM - SEC Filing
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
April 15, 2026 5:31 PM - SEC Filing
Form 4 Vor Biopharma Inc. For: Apr 13 Filed by: Kolchinsky Peter
April 15, 2026 5:30 PM - SEC Filing
Vor Biopharma, Inc. (VOR) PT Lowered to $31 at H.C. Wainwright
April 15, 2026 7:17 AM - StreetInsider
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
April 10, 2026 6:25 PM - SEC Filing
Form 4 Vor Biopharma Inc. For: Apr 08 Filed by: Kolchinsky Peter
April 10, 2026 6:24 PM - SEC Filing
Form 3 Vor Biopharma Inc. For: Apr 01 Filed by: Sokolove Jeremy Brett
April 9, 2026 8:02 PM - SEC Filing
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
April 8, 2026 6:45 PM - SEC Filing
Vor Biopharma (VOR) Reiterated at Buy by Stifel After Meetings About Telitacicept Potential
April 8, 2026 7:24 AM - StreetInsider
Form 4 Vor Biopharma Inc. For: Apr 02 Filed by: Kolchinsky Peter
April 6, 2026 6:57 PM - SEC Filing
Form SCHEDULE 13G Vor Biopharma Inc. Filed by: TCG Crossover GP II, LLC
April 1, 2026 5:29 PM - SEC Filing
Form 3 Vor Biopharma Inc. For: Mar 30 Filed by: TCG Crossover GP III, LLC
April 1, 2026 5:16 PM - SEC Filing
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
April 1, 2026 5:10 PM - SEC Filing
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2026 5:00 PM - Globe NewsWire
Vor Biopharma, Inc. (VOR) PT Lowered to $48 at Jefferies
March 30, 2026 5:30 PM - StreetInsider
Vor Biopharma, Inc. (VOR) PT Lowered to $40 at Stifel
March 30, 2026 2:30 PM - StreetInsider
Form S-8 Vor Biopharma Inc.
March 30, 2026 8:08 AM - SEC Filing
Form 10-K Vor Biopharma Inc. For: Dec 31
March 30, 2026 8:03 AM - SEC Filing
Vor Bio starts global phase 3 trial for Sjogren's disease treatment
March 30, 2026 8:01 AM - StreetInsider
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 30, 2026 8:01 AM - Globe NewsWire
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
March 30, 2026 8:00 AM - Globe NewsWire
Jefferies Starts Vor Biopharma, Inc. (VOR) at Buy
March 29, 2026 11:42 AM - StreetInsider
Form 8-K Vor Biopharma Inc. For: Mar 26
March 27, 2026 8:03 AM - SEC Filing
Vor Bio raises $75 million in private placement led by TCGX
March 27, 2026 8:01 AM - StreetInsider
Vor Bio Announces $75 Million Private Placement with TCGX
March 27, 2026 8:01 AM - Globe NewsWire
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 23, 2026 4:30 PM - Globe NewsWire
Wells Fargo Starts Vor Biopharma, Inc. (VOR) at Overweight
March 19, 2026 5:11 AM - StreetInsider
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
March 16, 2026 4:16 PM - SEC Filing
Full Article List
